OraSure files 510(k) for drugs-of-abuse diagnostic:
This article was originally published in Clinica
OraSure Technologies has filed a 510(k) application with the US FDA for permission to market its point-of-care oral fluid drugs-of-abuse diagnostic system. The UPlink reader has been submitted to the agency together with assays for detecting cocaine, opiates and amphetamines. The Bethlehem, Pennsylvania company plans to submit two additional tests - for marijuana and phencyclidine - within the next two months. The UPlink system is also being developed for gastrointestinal and respiratory infectious disease testing under an agreement with Meridian Diagnostics.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.